61. 自己免疫性溶血性貧血 Disease details / Clinical trials / Drug dev / DR info

2019171-69-6
   APELLIS PHARMACEUTCIALS, INC.
      2018   Phase 2   EUCTR2017-003363-35-IT   Italy;United States
   SWEDISH ORPHAN BIOVITRUM AB (PUBL)
      2022   Phase 3   EUCTR2021-003160-27-IT   Austria;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Norway;Russian Federation;Spain;Ukraine;United Kingdom;United States
   Swedish Orphan Biovitrum AB
      2023   Phase 3   EUCTR2021-003160-27-BE   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-NO   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-HU   Austria;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Norway;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-ES   Austria;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Norway;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-DE   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-BG   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-AT   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
Acalabrutinib
   City of Hope Medical Center
      2021   Phase 2   NCT04657094   United States
ACT-HIB polvere E solvente PER soluzione iniettabile IN siringa preriempita 0,5 ML
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
ALXN1830
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001211-90-IT   France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
   Alexion Pharmaceuticals
      2022   Phase 2   NCT04956276   United States
      2021   Phase 2   NCT04256148   United States
      2018   Phase 1/Phase 2   NCT03075878   Jordan;United States
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2021-001211-90-ES   France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004055-37-ES   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
ANTI-CD38 antibody injection
   Institute of Hematology & Blood Diseases Hospital, China
      2023   Phase 2   NCT06014775   China
ANX005
   Annexon, Inc
      2020   Phase 2   EUCTR2020-003675-18-IT   Austria;Bulgaria;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Norway;Spain;United Kingdom
   Annexon, Inc.
      2021   Phase 2   NCT04691570   United States
      2021   Phase 2   EUCTR2020-005854-90-AT   Austria
      2021   Phase 2   EUCTR2020-003675-18-FR   Australia;Austria;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003675-18-DE   Australia;Austria;Bulgaria;Czechia;France;Germany;Italy;Spain;United States
      2021   Phase 2   EUCTR2020-003675-18-BG   Australia;Austria;Bulgaria;Czechia;France;Germany;Italy;Spain;United States
      2021   Phase 2   EUCTR2020-003675-18-AT   Australia;Austria;Bulgaria;Czechia;France;Germany;Italy;Spain;United Kingdom;United States
APL-2
   APELLIS PHARMACEUTCIALS, INC.
      2018   Phase 2   EUCTR2017-003363-35-IT   Italy;United States
   Apellis Pharmaceuticals, Inc.
      2017   Phase 2   NCT03226678   United States
   SWEDISH ORPHAN BIOVITRUM AB (PUBL)
      2022   Phase 3   EUCTR2021-003160-27-IT   Austria;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Norway;Russian Federation;Spain;Ukraine;United Kingdom;United States
   Swedish Orphan Biovitrum AB
      2023   Phase 3   EUCTR2021-003160-27-BE   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-NO   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-HU   Austria;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Norway;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-ES   Austria;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Norway;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-DE   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-BG   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-AT   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
Aspaveli
   Swedish Orphan Biovitrum AB
      2023   Phase 3   EUCTR2021-003160-27-BE   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-NO   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-DE   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-BG   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-AT   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
Atovaquone
   INCYTE CORPORATION
      2021   Phase 3   EUCTR2021-002844-66-IT   Austria;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
Bendamustine hydrochloride
   Department of Medicine, Haugesund Hospital
      2013   Phase 2   EUCTR2011-004835-30-FI   Denmark;Finland;Norway
      2013   Phase 2   EUCTR2011-004835-30-DK   Denmark;Finland;Norway
      2012   Phase 2   EUCTR2011-004835-30-NO   Denmark;Finland;Norway
Bendamustine, rituximab
   Helse Fonna
      2013   Phase 2   NCT02689986   Denmark;Finland;Norway
Bexsero – sospensione iniettabile – siringa preriempita
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
Biological assessment
   Centre Hospitalier Universitaire Dijon
      2022   Phase 2   NCT05089227   France
BIV009
   Bioverativ, a Sanofi company
      2015   Phase 1   NCT02502903   Austria
BIVV009
   BIOVERATIV THERAPEUTICS INC
      2018   Phase 3   EUCTR2017-003539-12-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003538-10-IT   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
   Bioverativ USA Inc.
      2018   Phase 3   EUCTR2017-003539-12-NL   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003539-12-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003539-12-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003538-10-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003538-10-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003538-10-BE   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2017-003539-12-AT   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2017-003538-10-AT   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
   Bioverativ USA, Inc.
      2018   Phase 3   EUCTR2017-003539-12-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003539-12-BE   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003538-10-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
   Bioverativ a Sanofi Company Inc.
      2018   Phase 3   EUCTR2017-003538-10-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2017-003538-10-NO   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
   Bioverativ, a Sanofi company
      2018   Phase 3   NCT03347422   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
   Tanaka Tomoyuki
      2021   Phase 3   JPRN-jRCT2031210392   -
BIVV020
   Bioverativ, a Sanofi company
      2020   Phase 1   NCT04269551   Canada;Germany;Italy;Netherlands;Norway;Spain;United Kingdom;United States
Blood sample
   Centre Hospitalier Universitaire Dijon
      2016   -   NCT02828670   France
   University Hospital, Bordeaux
      2019   -   NCT04005638   France
      2019   -   NCT03912129   -
Blood samples
   Centre Hospitalier Universitaire Dijon
      2013   -   NCT02158195   France
Bortezomib
   Gruppo Italiano Malattie EMatologiche dell'Adulto
      2012   Phase 2   NCT01696474   Italy
CC312
   CytoCares Inc
      2024   Early Phase 1   NCT06888960   China
CD19/bcma CAR T-cells
   Zhejiang University
      2021   Early Phase 1   NCT05263817   China
Ciclosporin
   Tianjin Medical University General Hospital
      2019   Phase 0   ChiCTR1900023476   China
CNCT19 CAR-T cell therapy
   Institute of Hematology & Blood Diseases Hospital, China
      2024   Phase 1   NCT06231368   China
Combination OF A single dose ANTI-CD20 antibody and bortezomib
   Peking Union Medical College Hospital
      2019   Phase 2   NCT04083014   China
Complement C1 esterase inhibitor
   Bioverativ USA Inc.
      2018   Phase 3   EUCTR2017-003539-12-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003538-10-ES   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
   Bioverativ USA, Inc.
      2018   Phase 3   EUCTR2017-003538-10-NL   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States
Cyclosporine
   Assiut University
      2021   Phase 3   NCT05057468   Egypt
Cytokine essays
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2019   -   NCT05931718   Italy
Eculizumab
   University Hospital, Essen
      2011   Phase 2   NCT01303952   Germany
Efalizumab
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal
      2008   Phase 4   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal
Eliquis
   CHU Dijon Bourgogne
      2021   Phase 2   EUCTR2021-002358-99-FR   France
Erythropoietin
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2019   -   NCT05931718   Italy
Famotidina
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
Fecal microbiome
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2019   -   NCT05931718   Italy
Fludarabine
   University of Bergen
      2005   Phase 2   NCT00373594   Norway;Russian Federation
Fostamatinib 150 MG BID
   Rigel Pharmaceuticals
      2016   Phase 2   NCT02612558   Canada;United States
Fostamatinib disodium
   RIGEL PHARMACEUTICALS, INC.
      2020   Phase 3   EUCTR2019-001882-34-IT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-IT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
   Rigel Pharmaceuticals
      2019   Phase 3   NCT04138927   Australia;Austria;Belarus;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   NCT03764618   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
   Rigel Pharmaceuticals, Inc.
      2021   Phase 3   EUCTR2019-001882-34-NL   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-HU   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-GB   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-FR   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-ES   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-DE   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-CZ   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-AT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004774-97-RO   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004774-97-NL   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-HU   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-GB   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-ES   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-DK   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-DE   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-CZ   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-BG   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-BE   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-AT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
G-CSF
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2019   -   NCT05931718   Italy
GL-0719
   Gliknik Inc.
      2022   Phase 1   NCT05318534   United Kingdom
Hiberix - polvere E solvente PER soluzione iniettabile PER USO intramuscolare 1 flaconcino DI polvere + 1 siringa preriempita DI solvente DA 0.5 ML
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
Ianalumab
   NOVARTIS PHARMA AG
      2023   Phase 3   EUCTR2022-001773-31-IT   Argentina;Australia;China;France;Germany;Hungary;India;Israel;Italy;Japan;Malaysia;Romania;Singapore;Spain;Taiwan;Thailand;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2023   Phase 3   EUCTR2022-001773-31-ES   Argentina;Australia;China;France;Germany;Hungary;India;Israel;Italy;Japan;Malaysia;Singapore;Spain;Taiwan;Thailand;United Kingdom;United States
   Novartis Pharma AG
      2023   Phase 3   EUCTR2022-001773-31-RO   Argentina;Australia;China;France;Germany;Hungary;India;Israel;Italy;Japan;Malaysia;Romania;Singapore;Spain;Taiwan;Thailand;United Kingdom;United States
   Novartis Pharmaceuticals
      2022   Phase 3   NCT05648968   Argentina;Australia;China;France;Germany;Hungary;India;Israel;Italy;Japan;Malaysia;Romania;Singapore;Spain;Taiwan;Thailand;United Kingdom;United States
IASO-782 injection
   Shanghai IASO Biotechnology Co., Ltd
      2024   Phase 1   NCT06534021   -
Ibrutinib
   Eugene Nikitin
      2017   Phase 2   NCT03827603   Russian Federation
   Institute of Hematology & Blood Diseases Hospital, China
      2020   Phase 2   NCT04398459   China
Ibrutinib 420 MG
   Gruppo Italiano Malattie EMatologiche dell'Adulto
      2023   Phase 2   NCT05694312   Italy
INCB050465
   Ueda Eiji
      2021   Phase 3   JPRN-jRCT2051210140   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;U.S.A;United Kingdom
INCB050465 1 MG
   INCYTE CORPORATION
      2018   Phase 2   EUCTR2017-003652-22-IT   Austria;France;Italy;United States
   Incyte Coorporation
      2018   Phase 2   EUCTR2017-003652-22-AT   Austria;France;Italy;United States
   Incyte Corporation
      2018   Phase 2   EUCTR2017-003652-22-FR   Austria;France;Italy;United States
INCB050465 2.5 MG
   INCYTE CORPORATION
      2018   Phase 2   EUCTR2017-003652-22-IT   Austria;France;Italy;United States
   Incyte Coorporation
      2018   Phase 2   EUCTR2017-003652-22-AT   Austria;France;Italy;United States
   Incyte Corporation
      2018   Phase 2   EUCTR2017-003652-22-FR   Austria;France;Italy;United States
INCB050465 hydrochloride
   INCYTE CORPORATION
      2021   Phase 3   EUCTR2021-002844-66-IT   Austria;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
   Incyte Coorporation
      2018   Phase 2   EUCTR2017-003652-22-AT   Austria;France;Italy;United States
   Incyte Corporation
      2023   Phase 3   EUCTR2021-002844-66-HU   Australia;Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002844-66-NL   Australia;Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002844-66-FR   Australia;Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002844-66-ES   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002844-66-DE   Austria;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002844-66-AT   Australia;Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003652-22-FR   Austria;France;Italy;United States
Interleukine-2
   University Hospital, Bordeaux
      2017   Phase 1/Phase 2   NCT02389231   France
Iptacopan
   Bing Han
      2025   -   NCT06847607   China
   Novartis Farmacéutica, S.A.
      2021   Phase 2   EUCTR2021-002039-40-ES   Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
   Novartis Pharmaceuticals
      2021   Phase 2   NCT05086744   Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
Iptacopan hydrochloride
   Novartis Pharma AG
      2021   Phase 2   EUCTR2021-002039-40-DE   Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
Isatuximab
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
   Sanofi-Aventis Recherche & Developpement
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-NL   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-BE   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
Isatuximab SAR650984
   Sanofi
      2021   Phase 2   NCT04661033   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
KZR-616
   Kezar Life Sciences, Inc.
      2020   Phase 2   NCT04039477   Australia;Italy;Poland;Russian Federation;United States
Levact
   Department of Medicine, Haugesund Hospital
      2013   Phase 2   EUCTR2011-004835-30-FI   Denmark;Finland;Norway
      2013   Phase 2   EUCTR2011-004835-30-DK   Denmark;Finland;Norway
      2012   Phase 2   EUCTR2011-004835-30-NO   Denmark;Finland;Norway
Levamisole
   Institute of Hematology & Blood Diseases Hospital
      2012   Phase 2   NCT01579110   China
Levocetirizina dicloridrato
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
Levocitirizina
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
Linperlisib
   Institute of Hematology & Blood Diseases Hospital, China
      2023   Phase 1   NCT05676697   China
LNP023
   Novartis Farmacéutica, S.A.
      2021   Phase 2   EUCTR2021-002039-40-ES   Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
   Novartis Pharma AG
      2021   Phase 2   EUCTR2021-002039-40-DE   Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
Luspatercept
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2019   -   NCT05931718   Italy
M281
   Janssen Research & Development, LLC
      2019   Phase 2/Phase 3   NCT04119050   Brazil;Canada;China;Czechia;Egypt;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
   Janssen-Cilag International NV
      2020   Phase 2;Phase 3   EUCTR2019-000720-17-NL   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2;Phase 3   EUCTR2019-000720-17-DE   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-PL   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-HU   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-GR   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-CZ   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
   MOMENTA PHARMACEUTICALS, Inc
      2019   Phase 3   EUCTR2019-000720-17-IT   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
   Momenta Pharmaceuticals, Inc.
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-ES   Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Mabthera
   Assistance Publique - Hôpitaux de Paris
      2011   Phase 3   NCT01181154   France
   Department of Medicine, Haugesund Hospital
      2013   Phase 2   EUCTR2011-004835-30-FI   Denmark;Finland;Norway
      2013   Phase 2   EUCTR2011-004835-30-DK   Denmark;Finland;Norway
      2012   Phase 2   EUCTR2011-004835-30-NO   Denmark;Finland;Norway
   University Hospital, Toulouse
      2009   -   NCT00960713   France
Mabthera or biosimilar rituximab
   Medical University of Vienna, Department of Internal medicine I
      2016   Phase 2   EUCTR2016-002478-11-AT   Austria
Menveo – polvere E soluzione PER soluzione iniettabile
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
Montelukast
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
Mycophenolate mofetil 500MG
   Assiut University
      2021   Phase 3   NCT05057481   Egypt
N/A
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001211-90-IT   France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
   Janssen-Cilag International NV
      2020   Phase 2;Phase 3   EUCTR2019-000720-17-NL   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2;Phase 3   EUCTR2019-000720-17-DE   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-PL   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-HU   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-GR   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-CZ   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
   Momenta Pharmaceuticals, Inc.
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-ES   Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
NGS
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2019   -   NCT05931718   Italy
Nimenrix
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
Ninlaro
   Assistance Publique - Hôpitaux de Paris
      2019   Phase 2   NCT03965624   France
Nipocalimab
   Janssen Research & Development, LLC
      2022   -   NCT05221619   -
   Janssen-Cilag International NV
      2020   Phase 2;Phase 3   EUCTR2019-000720-17-NL   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2020   Phase 2;Phase 3   EUCTR2019-000720-17-DE   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-PL   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-HU   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-GR   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2019   Phase 2;Phase 3   EUCTR2019-000720-17-CZ   Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
Obexelimab
   Sato Toshiyuki
      2024   Phase 3   JPRN-jRCT2021230052   ITALY;Japan;POLAND;SPAIN;TAIWAN;TURKEY;UNITED KINGDOM;UNITED STATES
   Zenas BioPharma (USA), LLC
      2023   Phase 3   NCT05786573   Italy;Japan;Poland;Spain;Taiwan;Turkey;United Kingdom;United States
Orelabrutinib
   Tianjin Medical University General Hospital
      2021   Phase 4   ChiCTR2100045594   China
Orilanolimab
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2021-001211-90-IT   France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2021-001211-90-ES   France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004055-37-ES   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
Paracetamolo
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
Paraclisib
   Incyte Corporation
      2022   Phase 3   EUCTR2021-002844-66-DE   Austria;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
Parsaclisib
   INCYTE CORPORATION
      2021   Phase 3   EUCTR2021-002844-66-IT   Austria;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
   Incyte Corporation
      2023   Phase 3   EUCTR2021-002844-66-HU   Australia;Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002844-66-NL   Australia;Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002844-66-FR   Australia;Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002844-66-ES   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002844-66-DE   Austria;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-002844-66-AT   Australia;Austria;Belgium;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2018   Phase 2   NCT03538041   Austria;France;Italy;United States
   Ueda Eiji
      2021   Phase 3   JPRN-jRCT2051210140   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;U.S.A;United Kingdom
Parsaclisinib
   Incyte Corporation
      2022   Phase 3   NCT05073458   Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
Pegcetacoplan
   Haruki Maeda
      2023   Phase 3   JPRN-jRCT2031220441   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;UK;USA
   SWEDISH ORPHAN BIOVITRUM AB (PUBL)
      2022   Phase 3   EUCTR2021-003160-27-IT   Austria;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Norway;Russian Federation;Spain;Ukraine;United Kingdom;United States
   Swedish Orphan Biovitrum
      2022   Phase 3   NCT05096403   Austria;Belgium;Canada;Finland;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
   Swedish Orphan Biovitrum AB
      2023   Phase 3   EUCTR2021-003160-27-BE   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-NO   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-HU   Austria;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Norway;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-ES   Austria;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Norway;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-DE   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-BG   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2021-003160-27-AT   Austria;Belgium;Bulgaria;Canada;Finland;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
Pentamidina isetionato
   INCYTE CORPORATION
      2021   Phase 3   EUCTR2021-002844-66-IT   Austria;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
Pentamidine
   INCYTE CORPORATION
      2021   Phase 3   EUCTR2021-002844-66-IT   Austria;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
Povetacicept
   Alpine Immune Sciences, Inc.
      2023   Phase 1/Phase 2   NCT05757570   Australia;Austria;Canada;Germany;Italy;Norway;Spain;Turkey;United Kingdom;United States
Prednisolone + mabthera
   Copenhagen University Hospital at Herlev
      2005   Phase 3   NCT01134432   Denmark
Prednisone
   Institute of Hematology & Blood Diseases Hospital
      2012   Phase 2   NCT01579110   China
Prednisone, LOW dose rituximab
   Fondazione Ospedale
      2009   Phase 2   NCT01345708   Italy
PRN1008
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 2   EUCTR2021-001671-16-IT   China;Denmark;Italy;Spain;United Kingdom;United States
   Sanofi aventis recherche et developpement
      2023   Phase 2   EUCTR2021-001671-16-HU   Austria;China;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2021-001671-16-DE   Austria;China;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2021-001671-16-AT   Austria;China;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2021-001671-16-ES   China;Denmark;Italy;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2021-001671-16-DK   Austria;China;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;United States
R788, fostamatinib disodium hexahydrate (IN uspi/FPI)
   Rigel Pharmaceuticals, Inc.
      2020   Phase 3   EUCTR2019-001882-34-DK   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
R935788
   RIGEL PHARMACEUTICALS, INC.
      2020   Phase 3   EUCTR2019-001882-34-IT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-IT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
   Rigel Pharmaceuticals, Inc.
      2021   Phase 3   EUCTR2019-001882-34-NL   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-HU   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-GB   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-FR   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-ES   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-DE   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-CZ   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2019-001882-34-AT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004774-97-RO   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004774-97-NL   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-HU   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-GB   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-ES   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-DK   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-DE   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-CZ   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-BG   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-BE   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004774-97-AT   Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
Rapamycin
   Tianjin Medical University General Hospital
      2019   Phase 0   ChiCTR1900023476   China
Raptiva 100 MG/ML powder and solvent FOR solution FOR injection
   Merck Serono International S.A.
      2009   -   EUCTR2007-001377-28-PT   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-NL   Austria;France;Germany;Netherlands;Portugal
      2008   Phase 4   EUCTR2007-001377-28-FR   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-DE   Austria;France;Germany;Netherlands;Portugal
      2008   -   EUCTR2007-001377-28-AT   Austria;France;Germany;Netherlands;Portugal
Recombinant humanized IGG4 monoclonal antibody
   Annexon, Inc.
      2021   Phase 2   EUCTR2020-005854-90-AT   Austria
Rilzabrutinib
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 2   EUCTR2021-001671-16-IT   China;Denmark;Italy;Spain;United Kingdom;United States
   Sanofi
      2021   Phase 2   NCT05002777   Austria;China;Denmark;Germany;Hungary;Italy;Spain;United Kingdom;United States
   Sanofi aventis recherche et developpement
      2023   Phase 2   EUCTR2021-001671-16-HU   Austria;China;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2021-001671-16-DE   Austria;China;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2021-001671-16-AT   Austria;China;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2021-001671-16-ES   China;Denmark;Italy;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2021-001671-16-DK   Austria;China;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;United States
Rituxan
   University Hospital, Toulouse
      2009   -   NCT00960713   France
Rituximab
   Assistance Publique - Hôpitaux de Paris
      2011   Phase 3   NCT01181154   France
   Assiut University
      2021   Phase 3   NCT05057481   Egypt
      2021   Phase 3   NCT05057468   Egypt
   Beijing Children's Hospital, Capital Medical University
      2023   -   ChiCTR2400093312   China
   Department of Medicine, Haugesund Hospital
      2013   Phase 2   EUCTR2011-004835-30-FI   Denmark;Finland;Norway
      2013   Phase 2   EUCTR2011-004835-30-DK   Denmark;Finland;Norway
      2012   Phase 2   EUCTR2011-004835-30-NO   Denmark;Finland;Norway
   OSPEDALE MAGGIORE DI MILANO (IRCCS)
      2008   -   EUCTR2008-006713-25-IT   Italy
   University Hospital, Toulouse
      2009   -   NCT00960713   France
   University of Bergen
      2005   Phase 2   NCT00373594   Norway;Russian Federation
RVT-1401
   Immunovant Sciences GmbH
      2020   Phase 2   EUCTR2019-003924-19-PL   Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Spain;Thailand;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003924-19-HU   Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Spain;Thailand;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003924-19-GB   Israel;Korea, Republic of;Romania;Spain;Thailand;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003924-19-ES   Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Romania;Spain;Thailand;United Kingdom;United States
      2020   Phase 2   EUCTR2019-003924-19-BG   Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Spain;Thailand;United Kingdom;United States
SAR444671
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 2   EUCTR2021-001671-16-IT   China;Denmark;Italy;Spain;United Kingdom;United States
   Sanofi aventis recherche et developpement
      2023   Phase 2   EUCTR2021-001671-16-HU   Austria;China;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2021-001671-16-DE   Austria;China;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;United States
      2023   Phase 2   EUCTR2021-001671-16-AT   Austria;China;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2021-001671-16-ES   China;Denmark;Italy;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2021-001671-16-DK   Austria;China;Denmark;France;Germany;Hungary;Italy;Spain;United Kingdom;United States
SAR445088
   Bioverativ, a Sanofi company
      2021   Phase 1   NCT04802057   Germany;Italy;Netherlands;Norway;United Kingdom
SAR650984
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-IT   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
   Sanofi-Aventis Recherche & Developpement
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-NL   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-HU   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-DE   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
      2021   Phase 1;Phase 2   EUCTR2020-003880-24-BE   Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States
Sirolimus
   Children's Hospital of Philadelphia
      2006   Phase 1/Phase 2   NCT00392951   United States
   Peking Union Medical College Hospital
      2023   Phase 2   NCT05925023   China
Spleen sample
   Centre Hospitalier Universitaire Dijon
      2016   -   NCT02828670   France
Sutimlimab
   Bioverativ, a Sanofi company
      2018   Phase 3   NCT03347422   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
      2018   Phase 3   NCT03347396   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States
   Recordati Rare Diseases
      2019   -   NCT05791708   Austria;France;Germany;Italy;Japan;Spain;United Kingdom;United States
   Sanofi
      2021   Phase 3   NCT05132127   Japan
   Tanaka Tomoyuki
      2021   Phase 3   JPRN-jRCT2031210392   -
SYNT001
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2021-001211-90-ES   France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States
      2020   Phase 2   EUCTR2019-004055-37-ES   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States
Tacrolimus
   Peking Union Medical College Hospital
      2019   Phase 4   NCT03918265   China
Thiscart19A
   Institute of Hematology & Blood Diseases Hospital, China
      2024   Phase 1   NCT06212154   China
Thrombopoietin receptor agonist
   Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
      2019   -   NCT05931718   Italy
TNT009
   BIOVERATIV THERAPEUTICS INC
      2018   Phase 3   EUCTR2017-003539-12-IT   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003538-10-IT   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
   Bioverativ USA Inc.
      2018   Phase 3   EUCTR2017-003539-12-NL   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003539-12-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003538-10-DE   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003538-10-BE   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2017-003539-12-AT   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2017-003538-10-AT   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
   Bioverativ USA, Inc.
      2018   Phase 3   EUCTR2017-003539-12-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3   EUCTR2017-003539-12-BE   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
   Bioverativ a Sanofi Company Inc.
      2018   Phase 3   EUCTR2017-003538-10-GB   Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States
      2017   Phase 3   EUCTR2017-003538-10-NO   Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States
Treatment intervention
   Centre Hospitalier Universitaire Dijon
      2022   Phase 2   NCT05089227   France
Treatment standard
   Centre Hospitalier Universitaire Dijon
      2022   Phase 2   NCT05089227   France
Trimethoprim-sulfamethoxazole
   INCYTE CORPORATION
      2021   Phase 3   EUCTR2021-002844-66-IT   Austria;Belgium;Canada;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States
Ucar T-cell group
   Zhejiang University
      2025   Early Phase 1   NCT06920446   -
Universal allogeneic ANTI-CD19/bcma CAR T-cells
   Institute of Hematology & Blood Diseases Hospital, China
      2024   Phase 1   NCT06733610   China
Urine sample
   University Hospital, Bordeaux
      2019   -   NCT04005638   France
Vaccino contro IL memingococco DI gruppo B
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
Vaccino haemophilus influenzae B coniugato CON tossoidetetanico
   NOVARTIS PHARMA AG
      2022   Phase 2   EUCTR2021-002039-40-IT   Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States
VAY736
   NOVARTIS PHARMA AG
      2023   Phase 3   EUCTR2022-001773-31-IT   Argentina;Australia;China;France;Germany;Hungary;India;Israel;Italy;Japan;Malaysia;Romania;Singapore;Spain;Taiwan;Thailand;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2023   Phase 3   EUCTR2022-001773-31-ES   Argentina;Australia;China;France;Germany;Hungary;India;Israel;Italy;Japan;Malaysia;Singapore;Spain;Taiwan;Thailand;United Kingdom;United States
   Novartis Pharma AG
      2023   Phase 3   EUCTR2022-001773-31-RO   Argentina;Australia;China;France;Germany;Hungary;India;Israel;Italy;Japan;Malaysia;Romania;Singapore;Spain;Taiwan;Thailand;United Kingdom;United States
Velcade*EV 1FL 3,5MG 1MG/ML
   G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
      2012   Phase 2   EUCTR2011-006329-42-IT   Italy
YTS109
   Institute of Hematology & Blood Diseases Hospital, China
      2025   Phase 1   NCT06770504   -
Zanubrutinib
   Chen Miao
      2023   Phase 2   NCT05922839   China
   Institute of Hematology & Blood Diseases Hospital, China
      2023   Phase 2   NCT06021977   China
Zanubrutinib oral capsule
   Stichting Hemato-Oncologie voor Volwassenen Nederland
      2024   Phase 2   NCT06067048   Belgium;Denmark;Netherlands;Norway